AE37 HER2-targeted vaccine in the prevention of breast cancer recurrence: A mini narrative review of current evidence.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
29 Dec 2023
29 Dec 2023
Historique:
medline:
11
1
2024
pubmed:
11
1
2024
entrez:
11
1
2024
Statut:
ppublish
Résumé
Breast cancer remains a significant global health challenge, necessitating innovative therapeutic strategies. This review synthesizes findings from multiple studies investigating the safety profile and efficacy of the AE37 human epidermal growth factor receptor 2 (HER2)-targeted vaccine, offering insights into its potential role in breast cancer immunotherapy. A systematic search of electronic databases, including PubMed, MEDLINE, Scopus, and Web of Science, was conducted to identify relevant articles published up to October 2023. The search strategy utilized a combination of keywords, including "AE37 HER2 vaccine," "breast cancer recurrence prevention," and related terms. Boolean operators (AND, OR) were employed to refine the search. The AE37 vaccine exhibited a favorable safety profile across all studies, with minimal adverse effects reported. Efficacy outcomes varied, with promising trends observed in specific breast cancer subgroups, such as advanced-stage, HER2 under-expressed, and triple-negative breast cancer patients. Subgroup analyses suggested potential benefits, emphasizing the need for precise patient stratification. While the AE37 HER2-targeted vaccine demonstrates a promising safety profile and potential efficacy in specific breast cancer subgroups, an understanding requires addressing identified limitations and advancing research in nuanced directions. This paper provides a foundation for navigating the complex landscape of breast cancer immunotherapy with the AE37 vaccine.
Identifiants
pubmed: 38206732
doi: 10.1097/MD.0000000000036793
pii: 00005792-202312290-00051
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e36793Informations de copyright
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no funding and conflicts of interest to disclose.
Références
Łukasiewicz S, Czeczelewski M, Forma A, et al. Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. Cancers (Basel). 2021;13:4287.
Courtney D, Davey MG, Moloney BM, et al. Breast cancer recurrence: factors impacting occurrence and survival. Ir J Med Sci. 2022;191:2501–10.
Lafourcade A, His M, Baglietto L, et al. Factors associated with breast cancer recurrences or mortality and dynamic prediction of death using history of cancer recurrences: the French E3N cohort. BMC Cancer. 2018;18:171.
Ahmad A. Pathways to breast cancer recurrence. ISRN Oncol. 2013;2013:290568.
Pallerla S, Abdul AURM, Comeau J, et al. Cancer vaccines, treatment of the future: with emphasis on HER2-positive breast cancer. Int J Mol Sci. 2021;22:779.
Cronin KA, Harlan LC, Dodd KW, et al. Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. Cancer Invest. 2010;28:963–8.
Yang J, Ju J, Guo L, et al. Prediction of HER2-positive breast cancer recurrence and metastasis risk from histopathological images and clinical information via multimodal deep learning. Comput Struct Biotechnol J. 2021;20:333–42.
You Z, Zhou W, Weng J, et al. Application of HER2 peptide vaccines in patients with breast cancer: a systematic review and meta-analysis. Cancer Cell Int. 2021;21:489.
Mittendorf EA, Ardavanis A, Symanowski J, et al. Primary analysis of a prospective, randomised, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence. Ann Oncol. 2016;27:1241–8.
Sears AK, Perez SA, Clifton GT, et al. AE37: a novel T-cell-eliciting vaccine for breast cancer. Expert Opin Biol Ther. 2011;11:1543–50.
Brown TA 2nd, Mittendorf EA, Hale DF, et al. Prospective, randomised, single-blinded, multicenter phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence. Breast Cancer Res Treat. 2020;181:391–401.
Peace KM, Mittendorf EA, Perez SA, et al. Subgroup efficacy evaluation of the AE37 HER2 vaccine in breast cancer patients in the adjuvant setting. J Clin Oncol. 2017;35(15_suppl):3088–3088.
AE37. Immuno-Oncology News. Available at: https://immuno-oncologynews.com/ae37/ [access date October 3, 2023].
Tobias J, Garner-Spitzer E, Drinić M, et al. Vaccination against Her-2/neu, with focus on peptide-based vaccines. ESMO Open. 2022;7:100361.
Anastasopoulou EA, Voutsas IF, Papamichail M, et al. MHC class II tetramer analyses in AE37-vaccinated prostate cancer patients reveal vaccine-specific polyfunctional and long-lasting CD4(+) T-cells. Oncoimmunology. 2016;5:e1178439. Published May 2, 2016.
Gates JD, Clifton GT, Benavides LC, et al. Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide. Vaccine. 2010;28:7476–82.
Schneble EJ, Berry JS, Trappey AF, et al. Vaccine-specific T-cell proliferation in response to a dual peptide cancer vaccine in breast and ovarian cancer patients. J Immunother Cancer. 2013;1(Suppl 1):P236.